# Core 1: Systems Pathology Core

> **NIH NIH P01** · CEDARS-SINAI MEDICAL CENTER · 2023 · $269,026

## Abstract

CORE 1, SYSTEMS PATHOLOGY – SUMMARY
Sex differences in cancer risk, incidence, therapeutic response, and outcomes are well-known but poorly
understood. Sex disparities relating to bladder cancers involves an interplay between sex chromosomes, sex
hormones, and tumor micro-environment, including the immune cells and epigenomic alterations. The
overarching goal of the Systems Pathology Core (Core 1) is to support Program investigators by providing
streamlined and harmonized collection, processing and analysis of human and murine biospecimens to achieve
the aims outlined in the Program projects. This core will be co-led by Dr. Anil Parwani (The Ohio State University
Wexner Medical Center [OSUMC]) and Dr. Sergei Grivennikov (Cedars-Sinai Medical Center [CSMC]) and will
provide coordinated services for this multi-institutional Program. To accomplish core goals and avoid duplication
of services, Core 1 will work closely with resources at OSU, including the Comparative Pathology and Digital
Imaging Shared Resource, the Pathology Department, the Immune Monitoring and Discovery Platform, and the
Cooperative Human Tissue Network Midwestern network. At CSMC, Core 1 will utilize resources in the Flow
Cytometry, Advanced Genomics, and Mass Cytometry Shared Resources as well as Biobank Translational
Research Core.
The specific aims and services for the Systems Pathology Core are:
 Specific Aim 1. Act as a high-quality biorepository to collect, process, bank, and distribute annotated
 human and murine bladder cancer specimens and their derivatives for Program research.
 Specific Aim 2. Provide histology and pathology services to analyze human and murine bladder cancer
 biospecimens using immunohistochemistry and immunofluorescence with pathological characterization and
 spatial mapping (via Co-Detection by Indexing [CODEX]). This core will also provide pathologist diagnostic
 consultation, project planning, method development, scoring, interpretation, and manuscript writing.
 Specific Aim 3. Provide flow cytometry and single cell analysis services including multiparameter flow
 cytometry analysis and sorting, single cell RNA sequencing (scRNAseq), Cellular Indexing of Transcriptomes
 and Epitopes by Sequencing (CITEseq), Assay for Transposase-Accessible Chromatin using sequencing
 (ATACseq), mass cytometry (CyTOF), and standard molecular analyses. The core will harmonize processing
 and analysis techniques across Program sites to ensure data integrity and unified results.
The Systems Pathology Core will work closely with the Administrative Core and the Data Science Core,
which will provide robust data management and analysis of the data acquired herein.

## Key facts

- **NIH application ID:** 10629082
- **Project number:** 1P01CA278732-01
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** Anil V Parwani
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $269,026
- **Award type:** 1
- **Project period:** 2023-06-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10629082

## Citation

> US National Institutes of Health, RePORTER application 10629082, Core 1: Systems Pathology Core (1P01CA278732-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10629082. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*